The once powerful pharmaceutical lobby is in over its head.

For years, the industry was successful in fighting off efforts to provide senior citizens with low-cost drugs. But a presidential election year coupled with a close race in the House of Representatives has pushed the issue to the fore, and the drug makers’ lobby is in disarray.